The yin yang of sunitinib: One drug, two doses, and multiple outcomes
Our recent work showed that sunitinib exerts dual effect on cancer cells in different dose ranges. In clinically relevant doses, cancer cells tolerate sunitinb cytotoxicity by upregulating pro-survival MCL-1 and activating mTORC1 signaling. Inhibition of MCL-1 or mTORC1 sensitized cancer cells to su...
Main Author: | Mohamed Elgendy |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2017-03-01
|
Series: | Molecular & Cellular Oncology |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/23723556.2017.1285385 |
Similar Items
-
The Beneficial Role of Sunitinib in Tumor Immune Surveillance by Regulating Tumor PD‐L1
by: Hui Li, et al.
Published: (2021-01-01) -
Sunitinib induced hepatotoxicity in L02 cells via ROS-MAPKs signaling pathway
by: Ting-Li Tang, et al.
Published: (2022-10-01) -
Reciprocal Regulation between Primary Cilia and mTORC1
by: Yandong Lai, et al.
Published: (2020-06-01) -
The Bumpy Road towards mTOR Inhibition in Glioblastoma: Quo Vadis?
by: Kostas A. Papavassiliou, et al.
Published: (2021-12-01) -
Recent advances and limitations of mTOR inhibitors in the treatment of cancer
by: Eunus S. Ali, et al.
Published: (2022-09-01)